Various studies have shown a preferential overexpression of SET in chronic myelogenous leukemia [37], head and neck squamous cell carcinoma [38], non-small cell lung cancer [31], colorectal cancer [39], and breast cancer [19]. The gene discussed is SET; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.